Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.
Identifieur interne : 000547 ( Main/Exploration ); précédent : 000546; suivant : 000548Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.
Auteurs : Steven M. Smoke [États-Unis] ; Karan Raja [États-Unis] ; Patrick Hilden [États-Unis] ; Nicole M. Daniel [États-Unis]Source :
- International journal of antimicrobial agents [ 1872-7913 ] ; 2021.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Anticorps monoclonaux humanisés (usage thérapeutique), Antiviraux (usage thérapeutique), Facteurs temps (MeSH), Femelle (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Lopinavir (usage thérapeutique), Maladie grave (MeSH), Mâle (MeSH), Oxygène (administration et posologie), Oxygène (usage thérapeutique), Ritonavir (usage thérapeutique), Résultat thérapeutique (MeSH), Études rétrospectives (MeSH).
- MESH :
- administration et posologie : Oxygène.
- usage thérapeutique : Anticorps monoclonaux humanisés, Antiviraux, Hydroxychloroquine, Lopinavir, Oxygène, Ritonavir.
- Adulte d'âge moyen, Facteurs temps, Femelle, Humains, Maladie grave, Mâle, Résultat thérapeutique, Études rétrospectives.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Humanized (therapeutic use), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), COVID-19 (etiology), Critical Illness (MeSH), Female (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Lopinavir (therapeutic use), Male (MeSH), Middle Aged (MeSH), Oxygen (administration & dosage), Oxygen (therapeutic use), Retrospective Studies (MeSH), Ritonavir (therapeutic use), Time Factors (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , administration & dosage : Oxygen.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antiviral Agents, Hydroxychloroquine, Lopinavir, Oxygen, Ritonavir.
- drug therapy : COVID-19.
- etiology : COVID-19.
- Critical Illness, Female, Humans, Male, Middle Aged, Retrospective Studies, Time Factors, Treatment Outcome.
Abstract
Severe COVID-19 (coronavirus disease 2019) is associated with elevated inflammatory markers, consistent with cytokine release syndrome (CRS). Tocilizumab is an interleukin-6 (IL-6) inhibitor effective in treating CRS secondary to chimeric antigen receptor T-cell (CAR T-cell) therapy. The efficacy of tocilizumab in treating COVID-19 is unknown. This was a retrospective cohort study conducted at two hospitals in northern New Jersey (USA). All patients treated with tocilizumab for confirmed or suspected COVID-19 between 10 March 2020 and 9 April 2020 at the study sites were included. The primary endpoint was clinical improvement on Day 7 after treatment as assessed by respiratory status. Univariate analysis compared data between those who improved and those who did not. A total of 45 severe and critically ill patients treated with tocilizumab for COVID-19 were evaluated. Of the 45 patients, 11 (24.4%), 22 (48.9%) and 12 (26.7%) patients improved, had no change or worsened by Day 7 after treatment, respectively. Lower white blood cell count and lactate dehydrogenase at the time of drug administration as well as shorter time from supplemental oxygen initiation to dosing were significantly associated with clinical improvement in the univariate analysis. In conclusion, tocilizumab administration was associated with a low rate of clinical improvement within 7 days in this cohort of severe and critically ill patients with COVID-19.
DOI: 10.1016/j.ijantimicag.2020.106265
PubMed: 33338559
PubMed Central: PMC7834231
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.</title><author><name sortKey="Smoke, Steven M" sort="Smoke, Steven M" uniqKey="Smoke S" first="Steven M" last="Smoke">Steven M. Smoke</name><affiliation wicri:level="2"><nlm:affiliation>Pharmacy Department, Saint Barnabas Medical Center, 94 Old Short Hills Road, Livingston, NJ 07039, USA. Electronic address: steven.smoke@rwjbh.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pharmacy Department, Saint Barnabas Medical Center, 94 Old Short Hills Road, Livingston, NJ 07039</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Raja, Karan" sort="Raja, Karan" uniqKey="Raja K" first="Karan" last="Raja">Karan Raja</name><affiliation wicri:level="2"><nlm:affiliation>Pharmacy Department, Clara Maass Medical Center, 1 Clara Maass Dr., Belleville, NJ 07109, USA. Electronic address: karan.raja@rwjbh.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pharmacy Department, Clara Maass Medical Center, 1 Clara Maass Dr., Belleville, NJ 07109</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Hilden, Patrick" sort="Hilden, Patrick" uniqKey="Hilden P" first="Patrick" last="Hilden">Patrick Hilden</name><affiliation wicri:level="2"><nlm:affiliation>Biostatistics Department, Saint Barnabas Medical Center, Livingston, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biostatistics Department, Saint Barnabas Medical Center, Livingston, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Daniel, Nicole M" sort="Daniel, Nicole M" uniqKey="Daniel N" first="Nicole M" last="Daniel">Nicole M. Daniel</name><affiliation wicri:level="2"><nlm:affiliation>Pharmacy Department, Clara Maass Medical Center, 1 Clara Maass Dr., Belleville, NJ 07109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pharmacy Department, Clara Maass Medical Center, 1 Clara Maass Dr., Belleville, NJ 07109</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33338559</idno><idno type="pmid">33338559</idno><idno type="doi">10.1016/j.ijantimicag.2020.106265</idno><idno type="pmc">PMC7834231</idno><idno type="wicri:Area/Main/Corpus">000639</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000639</idno><idno type="wicri:Area/Main/Curation">000639</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000639</idno><idno type="wicri:Area/Main/Exploration">000639</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.</title><author><name sortKey="Smoke, Steven M" sort="Smoke, Steven M" uniqKey="Smoke S" first="Steven M" last="Smoke">Steven M. Smoke</name><affiliation wicri:level="2"><nlm:affiliation>Pharmacy Department, Saint Barnabas Medical Center, 94 Old Short Hills Road, Livingston, NJ 07039, USA. Electronic address: steven.smoke@rwjbh.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pharmacy Department, Saint Barnabas Medical Center, 94 Old Short Hills Road, Livingston, NJ 07039</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Raja, Karan" sort="Raja, Karan" uniqKey="Raja K" first="Karan" last="Raja">Karan Raja</name><affiliation wicri:level="2"><nlm:affiliation>Pharmacy Department, Clara Maass Medical Center, 1 Clara Maass Dr., Belleville, NJ 07109, USA. Electronic address: karan.raja@rwjbh.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pharmacy Department, Clara Maass Medical Center, 1 Clara Maass Dr., Belleville, NJ 07109</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Hilden, Patrick" sort="Hilden, Patrick" uniqKey="Hilden P" first="Patrick" last="Hilden">Patrick Hilden</name><affiliation wicri:level="2"><nlm:affiliation>Biostatistics Department, Saint Barnabas Medical Center, Livingston, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biostatistics Department, Saint Barnabas Medical Center, Livingston, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Daniel, Nicole M" sort="Daniel, Nicole M" uniqKey="Daniel N" first="Nicole M" last="Daniel">Nicole M. Daniel</name><affiliation wicri:level="2"><nlm:affiliation>Pharmacy Department, Clara Maass Medical Center, 1 Clara Maass Dr., Belleville, NJ 07109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pharmacy Department, Clara Maass Medical Center, 1 Clara Maass Dr., Belleville, NJ 07109</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></analytic><series><title level="j">International journal of antimicrobial agents</title><idno type="eISSN">1872-7913</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (etiology)</term><term>Critical Illness (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Oxygen (administration & dosage)</term><term>Oxygen (therapeutic use)</term><term>Retrospective Studies (MeSH)</term><term>Ritonavir (therapeutic use)</term><term>Time Factors (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Facteurs temps (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Lopinavir (usage thérapeutique)</term><term>Maladie grave (MeSH)</term><term>Mâle (MeSH)</term><term>Oxygène (administration et posologie)</term><term>Oxygène (usage thérapeutique)</term><term>Ritonavir (usage thérapeutique)</term><term>Résultat thérapeutique (MeSH)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Oxygen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antiviral Agents</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Oxygen</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Oxygène</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antiviraux</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Oxygène</term><term>Ritonavir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Critical Illness</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Maladie grave</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe COVID-19 (coronavirus disease 2019) is associated with elevated inflammatory markers, consistent with cytokine release syndrome (CRS). Tocilizumab is an interleukin-6 (IL-6) inhibitor effective in treating CRS secondary to chimeric antigen receptor T-cell (CAR T-cell) therapy. The efficacy of tocilizumab in treating COVID-19 is unknown. This was a retrospective cohort study conducted at two hospitals in northern New Jersey (USA). All patients treated with tocilizumab for confirmed or suspected COVID-19 between 10 March 2020 and 9 April 2020 at the study sites were included. The primary endpoint was clinical improvement on Day 7 after treatment as assessed by respiratory status. Univariate analysis compared data between those who improved and those who did not. A total of 45 severe and critically ill patients treated with tocilizumab for COVID-19 were evaluated. Of the 45 patients, 11 (24.4%), 22 (48.9%) and 12 (26.7%) patients improved, had no change or worsened by Day 7 after treatment, respectively. Lower white blood cell count and lactate dehydrogenase at the time of drug administration as well as shorter time from supplemental oxygen initiation to dosing were significantly associated with clinical improvement in the univariate analysis. In conclusion, tocilizumab administration was associated with a low rate of clinical improvement within 7 days in this cohort of severe and critically ill patients with COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33338559</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7913</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of antimicrobial agents</Title><ISOAbbreviation>Int J Antimicrob Agents</ISOAbbreviation></Journal><ArticleTitle>Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.</ArticleTitle><Pagination><MedlinePgn>106265</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0924-8579(20)30485-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijantimicag.2020.106265</ELocationID><Abstract><AbstractText>Severe COVID-19 (coronavirus disease 2019) is associated with elevated inflammatory markers, consistent with cytokine release syndrome (CRS). Tocilizumab is an interleukin-6 (IL-6) inhibitor effective in treating CRS secondary to chimeric antigen receptor T-cell (CAR T-cell) therapy. The efficacy of tocilizumab in treating COVID-19 is unknown. This was a retrospective cohort study conducted at two hospitals in northern New Jersey (USA). All patients treated with tocilizumab for confirmed or suspected COVID-19 between 10 March 2020 and 9 April 2020 at the study sites were included. The primary endpoint was clinical improvement on Day 7 after treatment as assessed by respiratory status. Univariate analysis compared data between those who improved and those who did not. A total of 45 severe and critically ill patients treated with tocilizumab for COVID-19 were evaluated. Of the 45 patients, 11 (24.4%), 22 (48.9%) and 12 (26.7%) patients improved, had no change or worsened by Day 7 after treatment, respectively. Lower white blood cell count and lactate dehydrogenase at the time of drug administration as well as shorter time from supplemental oxygen initiation to dosing were significantly associated with clinical improvement in the univariate analysis. In conclusion, tocilizumab administration was associated with a low rate of clinical improvement within 7 days in this cohort of severe and critically ill patients with COVID-19.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smoke</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Saint Barnabas Medical Center, 94 Old Short Hills Road, Livingston, NJ 07039, USA. Electronic address: steven.smoke@rwjbh.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raja</LastName><ForeName>Karan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Clara Maass Medical Center, 1 Clara Maass Dr., Belleville, NJ 07109, USA. Electronic address: karan.raja@rwjbh.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilden</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biostatistics Department, Saint Barnabas Medical Center, Livingston, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniel</LastName><ForeName>Nicole M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Clara Maass Medical Center, 1 Clara Maass Dr., Belleville, NJ 07109, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Antimicrob Agents</MedlineTA><NlmUniqueID>9111860</NlmUniqueID><ISSNLinking>0924-8579</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IL-6 inhibitor</Keyword><Keyword MajorTopicYN="N">Immunomodulatory agents</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Tocilizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33338559</ArticleId><ArticleId IdType="pii">S0924-8579(20)30485-4</ArticleId><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106265</ArticleId><ArticleId IdType="pmc">PMC7834231</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Infect. 2020 Jul;81(1):e6-e12</Citation><ArticleIdList><ArticleId IdType="pubmed">32283162</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Sep 12;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32918755</ArticleId></ArticleIdList></Reference><Reference><Citation>West J Emerg Med. 2020 Jul 08;21(4):779-784</Citation><ArticleIdList><ArticleId IdType="pubmed">32726241</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Dec 10;383(24):2333-2344</Citation><ArticleIdList><ArticleId IdType="pubmed">33085857</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2021 Jan 1;181(1):32-40</Citation><ArticleIdList><ArticleId IdType="pubmed">33080017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation><ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>EClinicalMedicine. 2020 Jul 03;24:100426</Citation><ArticleIdList><ArticleId IdType="pubmed">32766541</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jul 17;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2020 May;27(5):1451-1454</Citation><ArticleIdList><ArticleId IdType="pubmed">32205856</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2021 Jan 1;181(1):41-51</Citation><ArticleIdList><ArticleId IdType="pubmed">33080002</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2021 Jan 1;181(1):24-31</Citation><ArticleIdList><ArticleId IdType="pubmed">33080005</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2020 Aug 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32860964</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation><ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Oct;92(10):1875-1883</Citation><ArticleIdList><ArticleId IdType="pubmed">32441789</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncologist. 2018 Aug;23(8):943-947</Citation><ArticleIdList><ArticleId IdType="pubmed">29622697</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Sep;56(3):106103</Citation><ArticleIdList><ArticleId IdType="pubmed">32712333</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Rheumatol. 2020 Oct;2(10):e603-e612</Citation><ArticleIdList><ArticleId IdType="pubmed">32838323</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Rheumatol. 2020 May-Jun;38(3):529-532</Citation><ArticleIdList><ArticleId IdType="pubmed">32359035</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Oct 6;324(13):1330-1341</Citation><ArticleIdList><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 May;46(5):846-848</Citation><ArticleIdList><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation><ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2020 Sep 23;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32979572</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>New Jersey</li></region></list><tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Smoke, Steven M" sort="Smoke, Steven M" uniqKey="Smoke S" first="Steven M" last="Smoke">Steven M. Smoke</name></region><name sortKey="Daniel, Nicole M" sort="Daniel, Nicole M" uniqKey="Daniel N" first="Nicole M" last="Daniel">Nicole M. Daniel</name><name sortKey="Hilden, Patrick" sort="Hilden, Patrick" uniqKey="Hilden P" first="Patrick" last="Hilden">Patrick Hilden</name><name sortKey="Raja, Karan" sort="Raja, Karan" uniqKey="Raja K" first="Karan" last="Raja">Karan Raja</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000547 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000547 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33338559
|texte= Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33338559" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |